Sign in

    Hunter Diamond

    Research Analyst at Diamond Equity Research LLC

    Hunter Diamond is Chief Executive Officer and Senior Equity Analyst at Diamond Equity Research LLC, specializing in micro-capitalization and small capitalization companies across various sectors. He has provided research coverage for firms such as Genius Group Limited, delivering in-depth fundamental analysis focused on emerging growth companies with a track record of enhancing investor visibility. With credentials including the CFA designation, Hunter began his investment research career prior to founding Diamond Equity Research and has consistently led initiatives to expand coverage of under-followed equities. He holds professional licensing as a CFA Charterholder, and his leadership has positioned Diamond Equity Research as a notable provider of institutional-quality research reports.

    Hunter Diamond's questions to BIOHARVEST SCIENCES (BHST) leadership

    Hunter Diamond's questions to BIOHARVEST SCIENCES (BHST) leadership • Q2 2025

    Question

    Hunter Diamond of Diamond Equity Research LLC asked about the timeline for the CDMO division to begin contributing more meaningfully to revenue. He also inquired about the composition of the CDMO pipeline, specifically the breakdown between early-stage and later-stage assets.

    Answer

    CEO Ilan Sobel projected that meaningful revenue contributions from the CDMO division will begin in early 2026 as current projects advance and new ones enter the pipeline. He emphasized the high value of current projects, including a multi-billion dollar fragrance opportunity and the Tate and Lyle partnership. Sobel also explained that the new 'Discovery Phase' service is designed to accelerate the intake of new high-value projects into stage one, thereby strengthening the future revenue stream.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to BIOHARVEST SCIENCES (BHST) leadership • Q2 2025

    Question

    Asked about the timeline for the CDMO business to ramp up and contribute more meaningfully to revenue, and requested details on the breakdown of contracts between different phases and where the company sees the most opportunity.

    Answer

    The CEO stated that meaningful revenue contributions from the CDMO business are expected to start in early 2026 as current projects advance through phases and new projects are signed. The current pipeline is significant, including a pharma partner already moved to Phase 2 for an approved drug, and multi-billion dollar opportunities with Tate & Lyle and a fragrance company. The new 'discovery' service is helping to convert more leads into Stage 1 projects.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to ProPhase Labs (PRPH) leadership

    Hunter Diamond's questions to ProPhase Labs (PRPH) leadership • Q3 2024

    Question

    The analyst asked about the strategy and progress regarding potential partnerships for the BE-Smart Esophageal Cancer Test, including the types of companies ProPhase is in discussions with.

    Answer

    The company is actively exploring partnerships with large, multi-billion-dollar cancer diagnostic testing companies as a path to commercialization. This strategy is seen as a way to leverage an established infrastructure, accelerate valuation, and reduce risk. The executive mentioned that these companies are keen to enter the esophageal cancer space and that ProPhase holds key IP. While discussions are ongoing and somewhat preliminary, they could accelerate quickly. A potential deal could involve upfront payments, milestones, and royalties.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Genius Group (GNS) leadership

    Hunter Diamond's questions to Genius Group (GNS) leadership • Q4 2022

    Question

    Hunter Diamond of Diamond Equity inquired about the company's strategic shift towards larger M&A targets and its approach to leveraging Artificial Intelligence in education.

    Answer

    Chairman and CEO Roger James Hamilton detailed that depressed market valuations have made larger companies more open to acquisitions, offering benefits like established compliance systems. Regarding AI, Hamilton explained that Genius Group's 'Genie AI' provides a competitive edge through hyper-personalization, leveraging student data that generic AI lacks. He confirmed the strategy is to integrate top external AI platforms rather than building proprietary technology from scratch.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Genius Group (GNS) leadership • Q3 2022

    Question

    Hunter Diamond of Diamond Equity inquired about the conversion rate of free students to paying students and the company's forward-looking marketing strategy.

    Answer

    CEO Roger Hamilton explained that the company is improving conversion by implementing the 'Genius formula,' a pathway that uses lower-cost workshops and memberships to build trust before upselling to high-ticket items like university degrees. He noted it takes approximately 3.5 contact points to convert a free user. Regarding marketing, Hamilton emphasized a focus on organic growth over paid ads, leveraging partners who bring their existing communities and viral growth from shareable assessments. He also cited the acquisition of Revealed Films as a strategy to attract students through high-quality documentary content, reducing reliance on traditional ad spend.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Genius Group (GNS) leadership • H1 2022

    Question

    Hunter Diamond of Diamond Equity Research LLC inquired about Genius Group's acquisition strategy, including the criteria for buying versus building and the strength of the current M&A pipeline. He also asked about the company's competitive positioning and demand trends in a potential recessionary environment, given the high cost of traditional education.

    Answer

    Chairman and CEO Roger Hamilton detailed that the acquisition strategy focuses on companies with digitizable content and an existing student base, enabling global expansion and new curriculum development, such as adding a blockchain concentration to a business degree. He noted a strong M&A pipeline in what he considers a buyer's market. Regarding the economic climate, Hamilton and CFO Erez Simha explained that high student debt and a potential recession position Genius Group favorably. They believe their lower-cost, skill-based entrepreneurial education will see increased demand as individuals seek to reskill and avoid traditional education costs.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Salarius Pharmaceuticals (SLRX) leadership

    Hunter Diamond's questions to Salarius Pharmaceuticals (SLRX) leadership • Q1 2022

    Question

    Hunter Diamond of Diamond Equity asked about Salarius's approach to hiring and recruiting professionals with experience in protein degradation and epigenetics, and how this strategy aligns with maintaining a capital-light operational model amidst a competitive talent market.

    Answer

    CEO David Arthur explained that Salarius operates an efficient, 'general contractor' model, outsourcing most preclinical and manufacturing work, which minimizes the need for significant headcount increases. He stated that while they will add resources to support clinical trials, they focus on hiring key talent and leveraging remote work. Arthur acknowledged the competitive 'war for talent' and confirmed the company takes measures to offer competitive compensation to attract and retain the necessary expertise to advance its drug development programs.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Salarius Pharmaceuticals (SLRX) leadership • Q4 2021

    Question

    Hunter Diamond of Diamond Equity asked a series of questions regarding recent Form 4 filings by management, the company's cash burn and runway, concerns about competition in the targeted protein degradation space, the rationale for comparing SP-3164 to avadomide, and key upcoming milestones.

    Answer

    CEO David Arthur, CFO Mark Rosenblum, and Director of Corporate Development Daniela Santiesteban provided responses. David Arthur clarified the Form 4s were for stock purchases made with annual bonuses, reflecting his confidence in the company. Mark Rosenblum stated the cash burn is manageable and the current cash position of $29.2 million provides sufficient runway through upcoming data readouts. Regarding competition, David Arthur viewed it as validation of the market's potential. Daniela Santiesteban explained that SP-3164 is a purified, more active version of avadomide, which de-risks its development. Finally, David Arthur outlined key milestones, including interim seclidemstat data in mid-2022 and preclinical SP-3164 data in late Q3/early Q4.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Salarius Pharmaceuticals (SLRX) leadership • Q3 2021

    Question

    Hunter Diamond of Diamond Equity Research inquired about the company's strategy for expanding its pipeline, asking about potential new epigenetic assets or other opportunities beyond the current focus.

    Answer

    Director and CEO David Arthur discussed a two-pronged approach to pipeline growth. He confirmed an internal, discovery-stage program for a second-generation LSD1 inhibitor. He also revealed that Salarius's strong financial position has led to proactive in-licensing inquiries from other companies for assets not necessarily in the epigenetic space, which the company is currently evaluating.

    Ask Fintool Equity Research AI

    Hunter Diamond's questions to Guardforce AI (GFAI) leadership

    Hunter Diamond's questions to Guardforce AI (GFAI) leadership • FY 2021

    Question

    Hunter Diamond asked about the biggest market misconceptions regarding GFAI, the strategy behind expanding into Dubai and Australia, the company's ideal acquisition criteria, and its competitive advantage in the Robotics-as-a-Service (RaaS) market.

    Answer

    Chairman Terence Yap addressed misconceptions by clarifying that GFAI is evolving beyond a simple cash logistics firm into a technology-focused company in robotics and cybersecurity. He stated that the expansions into Dubai and Australia were strategic moves to capitalize on smart city initiatives and the need for automation. Yap defined ideal acquisitions as companies with existing distribution networks to enable rapid market entry. He asserted GFAI's competitive edge in RaaS comes from being a service provider, not a hardware manufacturer, offering a recurring revenue model similar to its traditional security guarding business.

    Ask Fintool Equity Research AI